Rod Rohrich, M.D., is a Dallas-based plastic surgeon who is internationally famous for his surgical skills. He also teaches his craft at UT Southwestern Medical Center. One of the procedures he teaches to his students is rhinoplasty, or more commonly known as a nose job. He has written many articles and textbooks about rhinoplasty is considered one of the best surgeons in the business at this procedure.
He is one of the few plastic surgeons that can perform revision rhinoplasty. This procedure is one that corrects a person’s nose who previously had a nose job. This is a very difficult procedure to perform because of how delicate the nasal structures are. Much of Dr. Rod Rohrich’s writing and research is on this type of procedure so that other expert plastic surgeons and their patients can benefit from his knowledge.
Dr. Rod Rohrich also performs many breast surgery operations. He says that every patient presents a unique situation. He works with his patients to make decisions about what materials to use and what shape and size implant they wish to have. He says there are a pretty large number of options in regards to where to make incisions so that they are minimized in both number and appearance after the surgery is completed. He is also one of the co-founders of the AiRS Foundation which helps women who have had a mastectomy get breast reconstruction surgery.
Facelifts are also one of Dr. Rod Rohrich’s specialties. He is skilled at this surgery along with neck lift procedures. When he combines both of these procedures on one of his patients it is called a complete facial rejuvenation which results in a person looking much younger than their years. He has been teaching and otherwise contributing his knowledge about these procedures for decades.
Summer of 2017 was quite a roller coaster ride for Republican Mitt Romney, he recently revealed he had undergone surgery to remove a tumor that was slowly developing in his prostate. The surgery procedure was performed at the U.C. Irvine Hospital by Dr. Thomas Ahlering. The prognosis for the prostate cancer was deemed positive, it was successfully treated in surgery and the politician might be up and ready for a comeback and become Orrin Hatch’s successor if he plans on running for the U.S. Senate.
According to the The American Cancer Society, 161,360 men were diagnosed with prostate cancer during 2017. They estimated that those numbers could reach close to 164,690 in new cases by the end of 2018. Prostate cancer is a disease known to develop in men over forty years of age, six out of ten cases are diagnosed with the disease around the ages of 65 and up. Mitt Romney wasn’t the first known politician to have been diagnosed with prostate cancer, it happened to Colin Powell in 2013 and John Kerry when he was nominated to run for President. They all have received some form of surgical treatment and currently appear to have no signs of the disease.
Dr. David B. Samadi is a urologist from the Lenox Hill Hospital in New York, N.Y., he thinks the key to their positive outcome was because all of those politicians chose surgery for treatment. When his patients are diagnosed with prostate cancer, the first thing he must carefully decide is what type of treatment is best and weigh the pros and cons to his patients, radiation or surgery?
He states that surgery is highly recommended if the cancer is localized and not spreading past the prostate gland. He favors surgery because there’s a better chance for survival, a patient that chose radiation were twice as likely to die sooner. Radiation treatment could also cause serious side effects such as secondary cancers that develop in the colon, rectal area or bladder.
Dr. David B. Samadi currently serves as the Chairman of Urology and the Chief of Robotic Surgery at the Lenox Hill Hospital. He has performed over 7,000 prostate surgeries via the da Vinci robotic system and is one of the leading prostate surgeons in New York. He received a B.S. degree in Biochemistry at Stony Brook University and earned his M.D. degree from Stony Brook School of Medicine.